Adamas Announces Positive Results from Ph III Study of Gocovri in Parkinson’s Patients with Dyskinesia

Adamas Announces Positive Results from Ph III Study of Gocovri in Parkinson’s Patients with Dyskinesia

Source: 
CP Wire
snippet: 

Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) On 4/19/18 announced positive data from EASE LID 2, the company’s two-year Phase 3 open-label study of GOCOVRI™ (amantadine) extended release capsules, the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.